Tigress Financial analyst Ivan Feinseth initiated coverage with a Buy rating on USANA Health (USNA) today. The company’s shares closed yesterday at $84.72, close to its 52-week low of $75.27.
According to TipRanks.com, Feinseth is a top 100 analyst with an average return of 17.2% and a 71.3% success rate. Feinseth covers the Consumer Goods sector, focusing on stocks such as Dolby Laboratories, Campbell Soup, and Synaptics Inc.
Currently, the analyst consensus on USANA Health is a Moderate Buy with an average price target of $95, implying a 12.1% upside from current levels. In a report issued on April 3, Pivotal Research also reiterated a Buy rating on the stock with a $95 price target.
See today’s analyst top recommended stocks >>
Based on USANA Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $32.33 million. In comparison, last year the company had a net profit of $28.95 million.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, and Sense-beautiful science.
